(Q36181342)

12 August 2017

title

Ropinirole in the treatment of Parkinson's disease (English)

1 reference

12 August 2017

1 reference

Zesiewicz TA

1

1 reference

12 August 2017

Hauser RA

series ordinal

2

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 May 1999

1 reference

Expert Opinion on Investigational Drugs

12 August 2017

published in

1 reference

12 August 2017

volume

8

1 reference

12 August 2017

issue

5

1 reference

12 August 2017

page(s)

697-710

1 reference

Ropinirole (SK and F 101468) in the treatment of Parkinson's disease

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.697

Subtypes and localization of dopamine receptors in human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.697

Comparative Review of Dopamine Receptor Agonists in Parkinson's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.697

Effects of ergots on adenylate cyclase activity in the corpus striatum and pituitary

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.697

Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.697

3H-spiroperidol labels dopamine receptors in pituitary and brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.697

Localization of [3H]spiperone binding sites in the intermediate lobe of the rat pituitary gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.697

Dopamine receptors and brain function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.697

Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.697

Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.697

Adrenal medullary transplant to the striatum of patients with advanced Parkinson's disease: 1-year motor and psychomotor data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.697

Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.697

Does levodopa aggravate Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.697

A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.697

An introduction to the free radical hypothesis in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.697

Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.697

Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.697

Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.8.5.697

21 January 2018

Identifiers

DOI

10.1517/13543784.8.5.697

1 reference

12 August 2017

1 reference